Last reviewed · How we verify

Toviaz (Fesoterodine)

Weill Medical College of Cornell University · FDA-approved active Small molecule

Toviaz (Fesoterodine) is a Muscarinic M3 receptor antagonist Small molecule drug developed by Weill Medical College of Cornell University. It is currently FDA-approved for Overactive bladder with symptoms of urge incontinence, urgency, and frequency. Also known as: Toviaz.

Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.

Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.

At a glance

Generic nameToviaz (Fesoterodine)
Also known asToviaz
SponsorWeill Medical College of Cornell University
Drug classMuscarinic M3 receptor antagonist
TargetM3 muscarinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaUrology
PhaseFDA-approved

Mechanism of action

Fesoterodine blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing involuntary contractions. This anticholinergic action increases bladder capacity and reduces the urge to urinate, thereby decreasing episodes of urgency incontinence and frequency. The drug is a prodrug that is rapidly hydrolyzed to its active metabolite.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Toviaz (Fesoterodine)

What is Toviaz (Fesoterodine)?

Toviaz (Fesoterodine) is a Muscarinic M3 receptor antagonist drug developed by Weill Medical College of Cornell University, indicated for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.

How does Toviaz (Fesoterodine) work?

Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.

What is Toviaz (Fesoterodine) used for?

Toviaz (Fesoterodine) is indicated for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.

Who makes Toviaz (Fesoterodine)?

Toviaz (Fesoterodine) is developed and marketed by Weill Medical College of Cornell University (see full Weill Medical College of Cornell University pipeline at /company/weill-medical-college-of-cornell-university).

Is Toviaz (Fesoterodine) also known as anything else?

Toviaz (Fesoterodine) is also known as Toviaz.

What drug class is Toviaz (Fesoterodine) in?

Toviaz (Fesoterodine) belongs to the Muscarinic M3 receptor antagonist class. See all Muscarinic M3 receptor antagonist drugs at /class/muscarinic-m3-receptor-antagonist.

What development phase is Toviaz (Fesoterodine) in?

Toviaz (Fesoterodine) is FDA-approved (marketed).

What are the side effects of Toviaz (Fesoterodine)?

Common side effects of Toviaz (Fesoterodine) include Dry mouth, Constipation, Headache, Urinary retention, Blurred vision.

What does Toviaz (Fesoterodine) target?

Toviaz (Fesoterodine) targets M3 muscarinic acetylcholine receptor and is a Muscarinic M3 receptor antagonist.

Related